Compare CLPR & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLPR | XLO |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.8M | 49.8M |
| IPO Year | 2015 | 2021 |
| Metric | CLPR | XLO |
|---|---|---|
| Price | $3.00 | $7.87 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | ★ 47.7K | 29.6K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | ★ 10.73% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,997,000.00 | $43,766,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $168.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 5.82 | ★ 589.88 |
| 52 Week Low | $2.83 | $0.46 |
| 52 Week High | $4.61 | $9.25 |
| Indicator | CLPR | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 37.18 | 52.16 |
| Support Level | $2.95 | $0.62 |
| Resistance Level | $3.58 | $9.22 |
| Average True Range (ATR) | 0.14 | 0.45 |
| MACD | -0.05 | -0.19 |
| Stochastic Oscillator | 1.75 | 34.65 |
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.